Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The project was undertaking by Qilu Hospital of Shandong University and other 2 well-known
hospitals in China. In order to report the efficacy and safety of rituximab combining with
bortezomib for the treatment of adults with immune thrombocytopenia (ITP), compared to
rituximab alone .
Phase:
Phase 3
Details
Lead Sponsor:
Shandong University
Collaborators:
The Affiliated Hospital of Qingdao University Yantai Yuhuangding Hospital